A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain
暂无分享,去创建一个
N Benson | O Demin | N. Benson | P. H. van der Graaf | D. Nichols | E. Metelkin | O. Demin | E Metelkin | G L Li | D Nichols | P H van der Graaf | G. L. Li
[1] D. Gibson,et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.
[2] M. Glass,et al. Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences , 2007, British journal of pharmacology.
[3] T. Bisogno,et al. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity , 2000, FEBS letters.
[4] A. Hoffman,et al. Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus , 2000, The Journal of Neuroscience.
[5] Alan A. Wilson,et al. Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase. , 2013, Nuclear medicine and biology.
[6] J. Ramos,et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. , 2001, Journal of medicinal chemistry.
[7] Stephen P. H. Alexander,et al. Lack of effect of chronic pre‐treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system , 2012, British journal of pharmacology.
[8] Sean P. Brown,et al. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. , 1997, Journal of neurophysiology.
[9] J. Gertsch,et al. Evidence for Bidirectional Endocannabinoid Transport across Cell Membranes* , 2012, The Journal of Biological Chemistry.
[10] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[11] S. Gaetani,et al. Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.
[12] A. Lichtman,et al. Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation , 2009, The AAPS Journal.
[13] L. Petrocellis,et al. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action , 1998, Trends in Neurosciences.
[14] N Benson,et al. Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.
[15] G Vassart,et al. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.
[16] V. Di Marzo,et al. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. , 2003, Biochemical pharmacology.
[17] R K Jain,et al. Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.
[18] Patrick Dupont,et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor , 2007, Proceedings of the National Academy of Sciences.
[19] K. Hsu,et al. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.
[20] A. Makriyannis,et al. The Conformation, Location, and Dynamic Properties of the Endocannabinoid Ligand Anandamide in a Membrane Bilayer* , 2005, Journal of Biological Chemistry.
[21] G. Jay,et al. Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. , 2012, British journal of clinical pharmacology.
[22] T. Bonner,et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.
[23] J. Oller,et al. Consensus and controversy , 1984 .
[24] B. Birnir,et al. Endogenous Unsaturated C18 N-Acylethanolamines Are Vanilloid Receptor (TRPV1) Agonists* , 2005, Journal of Biological Chemistry.
[25] F. Piscitelli,et al. "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. , 2012, ACS chemical neuroscience.
[26] D-M Hu,et al. Time-dependent sensitivity analysis of biological networks: coupled MAPK and PI3K signal transduction pathways. , 2006, The journal of physical chemistry. A.
[27] C. Fowler,et al. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development? , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[28] Sheila Annie Peters,et al. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[29] J. Laitinen,et al. The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors , 2012, Acta physiologica.
[30] D. Lovinger,et al. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.
[31] T. Smart,et al. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.
[32] C. Hillard,et al. Cellular accumulation of anandamide: consensus and controversy , 2003, British journal of pharmacology.
[33] Igor Goryanin,et al. Kinetic modelling in systems biology , 2008 .
[34] L. Petrocellis,et al. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. , 2001, Biochemical and biophysical research communications.
[35] A. Yamashita,et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. , 1995, Biochemical and biophysical research communications.
[36] Tanezumab takes on pain due to osteoarthritis of the knee , 2008 .
[37] A. Lichtman,et al. In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects , 2014, British journal of pharmacology.
[38] P. Pacher,et al. The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.
[39] D. Julius,et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.
[40] L. Leventhal,et al. Predictive validity of animal pain models? A comparison of the pharmacokinetic–pharmacodynamic relationship for pain drugs in rats and humans , 2008, Neuropharmacology.
[41] G. Vauquelin,et al. Ligands, their receptors and … plasma membranes , 2009, Molecular and Cellular Endocrinology.
[42] Paul Morgan,et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. , 2012, Drug discovery today.
[43] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[44] K. Mackie,et al. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[45] N. Ueda,et al. Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase* , 2005, Journal of Biological Chemistry.
[46] N Benson,et al. Reducing systems biology to practice in pharmaceutical company research; selected case studies. , 2012, Advances in experimental medicine and biology.
[47] Benjamin F. Cravatt,et al. Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain , 2011, Journal of Pharmacology and Experimental Therapeutics.
[48] B. Cravatt,et al. Chemical Probes of Endocannabinoid Metabolism , 2013, Pharmacological Reviews.
[49] B. Hendriks. Negative Modeling Results: A Dime a Dozen or a Stepping Stone to Scientific Discovery? , 2013, CPT: pharmacometrics & systems pharmacology.
[50] D. Brown,et al. Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a Pertussis toxin‐sensitive mechanism , 1992, British journal of pharmacology.
[51] Frederick E. Petry,et al. Principles and Applications , 1997 .
[52] Z. Vogel,et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. , 1995, Biochemical pharmacology.